

# Drug/Medical Device Report

## Acambis PLC (CH121699BCN699:GB)

### 1. Abstract

This report examines the Drug/Medical Device pipeline of Acambis PLC (CH121699BCN699:GB), detailing each drug/device's indication, clinical trial status, and mechanism of action. Furthermore, this report identifies the Focus Sector of Acambis PLC (CH121699BCN699:GB), and analyzes its pipeline and performance against the Focus Sector to which it belongs. In summary, this Drug/Medical Device Report makes available 3 key pieces of data that help determine the performance and risk of Biotech, Pharmaceutical and Medical Device companies: (1) product/candidate pipeline, (2) product/candidate clinical trial status, and (3) product/candidate pipeline diversification.

### 2. Lines of Business Summary

- Acambis PLC (CH121699BCN699:GB) ranks 6 by market cap among the 7 companies focused in Healthcare > Biopharmaceuticals > Infectious Diseases > Viral and ranks 50 among all 52 companies participating in Viral.
- Acambis PLC (CH121699BCN699:GB) ranks 25 by market cap among the 28 companies focused in Healthcare > Biopharmaceuticals > Infectious Diseases and ranks 152 among all 166 companies participating in Infectious Diseases.
- Acambis PLC (CH121699BCN699:GB) ranks 303 by market cap among the 334 companies focused in Healthcare > Biopharmaceuticals and ranks 356 among all 401 companies participating in Biopharmaceuticals.
- Acambis PLC (CH121699BCN699:GB) has a Drug pipeline that is diversified across 1 of 21 disease sectors within Biopharmaceuticals.

CH121699BCN699:GB: Product Hierarchy Participation	Focus	CH121699BCN699: Companies GB Products by Sector		Focused Companies
<b>I</b> Healthcare	<b>P</b>	5	895	731
■ Biopharmaceuticals	<b>P</b>	5	401	334
◆ Infectious Diseases	<b>P</b>	5	166	28

### 3. Sector Performance



Name	Ticker	Last Price	Daily Return %	1 Month Return %	3 Month Return %	1 Year Return %	YTD Return %
Acambis PLC	CH121699B CN699:GB	n/a	n/a	n/a	n/a	n/a	n/a
Biopharmaceuticals	^BPHRM	481.72	0.88%	2.72%	4.16%	3.61%	14.58%
Infectious Diseases	^INFCT	538.42	0.70%	3.09%	-5.92%	9.53%	6.17%
Viral	^227899	1,470.13	0.88%	10.70%	1.68%	10.71%	18.25%
Vaccines	^228178	n/a	n/a	n/a	n/a	n/a	n/a

#### Recent Leaders and Laggards: Healthcare

##### Gainers

Name	Ticker	Market Cap.	3 Month Return %
------	--------	-------------	------------------

##### Decliners


Name	Ticker	Market Cap.	3 Month Return %
Sinovac Biotech Ltd	SVA	116.596	-1.83%

## 4. Pipeline Summary

### Biopharmaceuticals

	CH1216 99BCN6 99:GB	^BPHR M	^INFCT	^22789 9	^22817 8
Approved	1	14	7	6	6
Approval Pending	0	2	2	1	1
Phase III	1	5	2	2	2
Phase II	2	7	3	1	1
Phase I	2	6	3	0	0
Preclinical/Research	1	4	2	1	1
<b>Total Indications</b>	<b>7</b>	<b>21</b>	<b>8</b>	<b>7</b>	<b>6</b>
<b>Drugs</b>	<b>5</b>	<b>14</b>	<b>6</b>	<b>5</b>	<b>6</b>

The chart and table compare the number of drug indications in each stage of development for CH121699BCN699:GB to the median number of drug indications in each stage of development for its sectors (Focused companies only).



## 5. Late Stage Drug Candidates

Drug [Stage] Indication Drug Competition by Indication	Expected PDUFA PMOA [Proven PMOA?] Drug Competition by PMOA
<b>Acambis ChimeriVax [Phase III]</b>  <b>Indication:</b> Japanese Encephalitis Vaccine  <b>Competitors:</b> <ul style="list-style-type: none"> <li>- Sanofi (SNY) / Avian Flu (H5N1) Vaccine</li> <li>- Sanofi (SNY) / Flu Infants Vaccine</li> <li>- Sanofi (SNY) / Imovax Rabies Vero</li> <li>- Sanofi (SNY) / Acambis ChimeriVax</li> <li>- Sanofi (SNY) / Imojev (Japanese Encephalitis Vaccine)</li> </ul> More: 16 companies; 76 drugs (not shown)	Expected PDUFA: -  <b>POMA:</b> Japanese Encephalitis <b>Proven:</b> no  <b>Competitors:</b> <ul style="list-style-type: none"> <li>- Sanofi (SNY) / JE-VAX (Japanese Encephalitis Virus Vaccine)</li> <li>- Sanofi (SNY) / Acambis ChimeriVax</li> <li>- Sanofi (SNY) / Imojev (Japanese Encephalitis Vaccine)</li> <li>- Novartis SA (NVS) / Ixiaro (Japanese Encephalitis Vaccine)</li> </ul>

## 6. Product Lifecycle

Sector and Product Hierarchy Path	Indications	Side Effects	Stage of Development
<b>I Healthcare</b>			
■ Biopharmaceuticals			
◆ Infectious Diseases			
● <b>Phase I/Phase II Clinical Stage Products</b>			
ACAM-CDIFF C. difficile Vaccine	C. difficile Vaccine		Phase I
ACAM-FLU-A Influenza A Vaccine Program	Influenza A Vaccine (Flu Vaccine), Including Avian Influenza (H5N1) Vaccine		Phase I
Acambis ChimeriVax	West Nile Virus Vaccine		Phase II
Acambis ChimeriVax	Dengue Fever Vaccine		Phase II
Acambis ChimeriVax	Japanese Encephalitis Vaccine		Phase III
● <b>Research/Preclinical Stage Products</b>			
Acambis Herpes Simplex Virus (HSV) Vaccine	Herpes Simplex Virus (HSV) Vaccine		Preclinical
▲ Viral			
▲ Vaccines			
▲ Viral			
▲ Single Target			
● <b>Japanese Encephalitis</b>			
● <b>Variola (Smallpox)</b>			
ACAM2000 Smallpox Vaccine	Smallpox Vaccine	Itching, Swollen Lymph Nodes, Sore Arm, Fever, Headache, Body Ache, Mild Rash, Fatigue	Approved